On July 20, 2020, Synairgen plc (Southampton, United Kingdom) announced phase II results on 101 patients showing the odds of developing severe COVID-19 are reduced by 79% in patients receiving inhaled IFN-β treatment compared to placebo treatment. Here, IFNB1 is linked to COVID-19.